接受乳腺或胸壁放疗伴或不伴区域淋巴结照射的肤色有色人种患者发生放射性皮炎的风险
本研究纳入2015至2018年接受全乳或胸壁±区域淋巴结照射或高切线野放疗(50 Gy分25次)的325例患者,其中40%为肤色有色人种(Fitzpatrick IV-VI型)。多因素分析显示,黑种人/非裔美国人种族和胸壁照射与医生报告的2或3级急性放射性皮炎几率降低相关,而皮肤 bolus 和计划靶区D0.03cc体积与几率升高相关;肤色有色人种和皮肤 bolus 与晚期2或3级色素沉着几率升高相关。结论认为,尽管肤色有色人种患者医生报告的急性放射性皮炎几率较低,但晚期色素沉着几率较高,提示急性放射性皮炎可能被低估。
要点
- 黑种人/非裔美国人种族与医生报告的2或3级急性放射性皮炎几率降低相关(OR 0.110)。
- 胸壁照射与医生报告的2或3级急性放射性皮炎几率降低相关(OR 0.377)。
- 肤色有色人种与医生报告的晚期2或3级色素沉着几率升高相关(OR 3.658)。
核心结论
- 黑种人/非裔美国人患者医生报告的急性放射性皮炎几率较低,但肤色有色人种患者晚期色素沉着几率较高,且独立于自我报告的种族。
- 这些发现提示,尽管有晚期放射性皮肤毒性的证据,使用医生评定量表时肤色有色人种的急性放射性皮炎可能被低估。
研究设计与样本
- 研究纳入2015至2018年接受全乳或胸壁±区域淋巴结照射或高切线野放疗、剂量为50 Gy分25次的患者。
- 共325例患者符合条件,其中40%(n=129)为肤色有色人种(Fitzpatrick IV-VI型)。
- 采用多因素模型评估肤色有色人种与医生报告的急性放射性皮炎、晚期色素沉着以及口服和外用治疗使用之间的关联。
主要发现
- 多因素分析中,黑种人/非裔美国人种族与医生报告的2或3级急性放射性皮炎几率降低相关(OR 0.110;95%CI 0.030-0.397;P=.001)。
- 胸壁照射与医生报告的2或3级急性放射性皮炎几率降低相关(OR 0.377;95%CI 0.161-0.883;P=.025)。
- 皮肤 bolus 与医生报告的2或3级急性放射性皮炎几率升高相关(OR 8.029;95%CI 3.655-17.635;P=0)。
- 计划靶区D0.03cc与医生报告的2或3级急性放射性皮炎几率升高相关(OR 1.001;95%CI 1.000-1.001;P=.028)。
- 肤色有色人种(OR 3.658;95%CI 1.236-10.830;P=.019)和皮肤 bolus(OR 26.786;95%CI 4.235-169.432;P=0)与医生报告的晚期2或3级色素沉着几率升高相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Acute radiation dermatitis (ARD) is common after radiation therapy for breast cancer, with data indicating that ARD may disproportionately affect Black or African American (AA) patients. We evaluated the effect of skin of color (SOC) on physician-reported ARD in patients treated with radiation therapy. METHODS AND MATERIALS: We identified patients treated with whole breast or chest wall ± regional nodal irradiation or high tangents using 50 Gy in 25 fractions from 2015 to 2018. Baseline skin pigmentation was assessed using the Fitzpatrick scale (I = light/pale white to VI = black/very dark brown) with SOC defined as Fitzpatrick scale IV to VI. We evaluated associations among SOC, physician-reported ARD, late hyperpigmentation, and use of oral and topical treatments for RD using multivariable models. RESULTS: A total of 325 patients met eligibility, of which 40% had SOC (n = 129). On multivariable analysis, Black/AA race and chest wall irradiation had a lower odds of physician-reported grade 2 or 3 ARD (odds ratio [OR], 0.110; 95% confidence interval [CI], 0.030-0.397; P = .001; OR, 0.377; 95% CI, 0.161-0.883; P = .025), whereas skin bolus (OR, 8.029; 95% CI, 3.655-17.635; P = 0) and planning target volume D0.03cc (OR, 1.001; 95% CI, 1.000-1.001; P = .028) were associated with increased odds. On multivariable analysis, SOC (OR, 3.658; 95% CI, 1.236-10.830; P = .019) and skin bolus (OR, 26.786; 95% CI, 4.235-169.432; P = 0) were associated with increased odds of physician-reported late grade 2 or 3 hyperpigmentation. There was less frequent use of topical steroids to treat ARD and more frequent use of oral analgesics in SOC versus non-SOC patients (43% vs 63%, P < .001; 50% vs 38%, P = .05, respectively). CONCLUSIONS: Black/AA patients exhibited lower odds of physician-reported ARD. However, we found higher odds of late hyperpigmentation in SOC patients, independent of self-reported race. These findings suggest that ARD may be underdiagnosed in SOC when using the physician-rated scale despite this late evidence of radiation-induced skin toxicity.
引用
- Purswani JM, Bigham Z, Adotama P, et al. Risk of Radiation Dermatitis in Patients With Skin of Color Who Undergo Radiation to the Breast or Chest Wall With and Without Regional Nodal Irradiation. Int J Radiat Oncol Biol Phys. 2023. PMID: 37060928. doi:10.1016/j.ijrobp.2023.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。